Novartis Turns To OTC Co-Packers As Lincoln Plant Lags
This article was originally published in The Tan Sheet
Executive Summary
Originally expected back online by the summer, the Novartis Consumer Health facility in Lincoln, Neb., will not ship any product in 2012. Novartis, which reported consumer sales down 22% to $938 million in Q3, is using third-party manufacturers to restore Excedrin Migraine and other OTCs to market.
You may also be interested in...
FDA Pressure Likely In Novartis OTC Plant Shutdown, Recalls
FDA inspectors were in Novartis Consumer Health’s Lincoln, Neb., plant in December and January, as the company was deciding to halt production and recall products. An inspection report notes 10 observations – eight of them repeats from FDA’s visit in mid-2011.
Sandoz GMP Warning Letter: Is The Problem Documentation, Or Leadership?
Upper management at Novartis and Sandoz are responsible for repeated cGMP violations at three Sandoz plants, FDA suggests. The agency’s warning letter, aimed at three sites in North Amercia, includes what may become new biolerplate instructions on drug shortages.
NaZura’s Lovidia Weight-Loss Supplement Strategy Focused On Brand Building
NaZura BioHealth, spun out from Elcelyx Therapeutics, will market its Lovidia weight-loss product in 2014 when it launches into the direct-response channel, before potential suitors get serious about acquiring the brand.